Argon Plasma Coagulation for Barrett's Esophagus

Barretts Esophagus With Low Grade Dysplasia Clinical Trial

Official title: Argon Plasma Coagulation for Barrett's Esophagus With Low Grade Dysplasia: A Randomized Trial With Long Term Follow-up Evaluating the Impact of Power Setting and Proton Pump Inhibitor Dose

Status Completed

Clinical Trial Summary

Background and study aims. To evaluate the impact of power setting and proton pump inhibitor (PPI) dose on the efficacy and safety of argon plasma coagulation (APC) of Barrett's esophagus (BE) with low-grade dysplasia (LGD).

Patients and methods. Investigator initiated, single-center, parallel-group randomized controlled trial (RCT) conducted in a tertiary referral center in Poland. Consecutive patients with BE and LGD were randomly assigned to APC with power set at 90 Watt (90W) or 60 Watt (60W) followed by 120 mg or 40 mg omeprazole for six weeks. The primary outcome of the study was the rate of complete (endoscopic and histologic) ablation of BE at six weeks. Secondary outcomes included safety and long-term efficacy (at two years and at the end of a long-term follow-up of over 4 years.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Barrett Esophagus
• Barretts Esophagus With Low Grade Dysplasia

• NCT number: NCT04154748
• Study type: Interventional
• Source: Maria Sklodowska-Curie Institute - Oncology Center
• Status: Completed
• Phase: N/A
• Start date: June 4, 2002
• Completion date: July 5, 2019